Aventis’ Estorra Rights Acquired By Private Equity Firm For $115 Mil.

The company is divesting its rights in the insomnia drug as part of a Federal Trade Commission consent agreement clearing the Sanofi merger. Paul Royalty Fund II, an affiliate of Paul Capital Partners, will make fixed and milestone payments.